Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

Bristol Myers Squibb at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Bristol Myers Squibb brings 2 presentations to SITC 2026 in Phoenix. Its program covers new agents and the company's approach to scientific opportunity and partnerships. The most concrete topic is iza-bren, its first bispecific antibody-drug conjugate, and pumitamig, a bispecific antibody against PD-L1 and VEGF-A.

Organization	SITC 2026 Attendance
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global pharmaceutical company whose immuno-oncology medicines include the checkpoint inhibitors nivolumab and ipilimumab.	Talk Thu Nov 5 1:45pm–1:55pm Part of Session III: ADC/iADC Iza-bren: BMS's First Bispecific ADC, and Pumitamig, the PD-L1×VEGF-A Bispecific Antibody Valley of the Sun Ballroom New agents Talk Thu Nov 5 6:35pm–6:55pm Part of High-Impact Talks from Pharma Leaders BMS’s Approach to Scientific Opportunity and Strategic Partnership Regulatory Session Thu Nov 5 6:55pm–7:15pm Panel

Instantly find 20 buyers from Bristol Myers Squibb

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction